Research & Literature

Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).

Lastoria S, Marciello F, Faggiano A, et al.

Endocrine 2016; (52(3)):488-94 doi:10.1007/s12020-015-0702-y.

Animal models of spontaneous pancreatic neuroendocrine tumors.

Yu R

Molecular and cellular endocrinology 2016; (421()):60-7.

Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.

Clewemar Antonodimitrakis P, Sundin A, Wassberg C, et al.

Neuroendocrinology 2016; (103(3-4)):345-53 doi:10.1159/000439086.

Surgical Management of Pancreatic Neuroendocrine Tumors.

Clancy TE

Hematology/oncology clinics of North America 2016; (30(1)):103-18.

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Falconi M, Eriksson B, Kaltsas G, et al.

Neuroendocrinology 2016; (103(2)):153-71 doi:10.1159/000443171.

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Pokuri VK, Fong MK, Iyer R

Current oncology reports 2016; (18(1)):7 doi:10.1007/s11912-015-0492-7.

Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review.

Pezzilli R, Partelli S, Cannizzaro R, et al.

Advances in medical sciences 2016; (61(1)):147-53.

Islet Cell Tumors of the Pancreas.

Amin S, Kim MK

Gastroenterology clinics of North America 2016; (45(1)):83-100.

Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

Gut P, Czarnywojtek A, Fischbach J, et al.

Archives of medical science : AMS 2016; (12(1)):1-9 doi:10.5114/aoms.2016.57577.

Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1.

Lopez CL, Albers MB, Bollmann C, et al.

World journal of surgery 2016; (40(7)):1729-36 doi:10.1007/s00268-016-3456-7.

State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Tamm EP, Bhosale P, Lee JH, Rohren EM

Surgical oncology clinics of North America 2016; (25(2)):375-400.

Clinical treatment of gastrinoma: A case report and review of the literature.

Zhang WD, Liu DR, Wang P, et al.

Oncology letters 2016; (11(5)):3433-3437 doi:10.3892/ol.2016.4397.

Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

Qiu W, Christakis I, Silva A, et al.

Clinical endocrinology 2016; (85(3)):400-7 doi:10.1111/cen.13119.

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Raj N, Valentino E, Capanu M, et al.

Pancreas 2017; (46(3)):296-301 doi:10.1097/MPA.0000000000000735.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, et al.

The New England journal of medicine 2017; (376(2)):125-135 doi:10.1056/NEJMoa1607427.

Solid pseudopapillary neoplasm of the pancreas: CT imaging features and radiologic-pathologic correlation.

Anil G, Zhang J, Al Hamar NE, Nga ME

Diagnostic and interventional radiology (Ankara, Turkey) 2017; (23(2)):94-99 doi:10.5152/dir.2016.16104.

Pancreatic neuroendocrine tumors.

Varas Lorenzo M, Cugat Andorra E, Capdevila Castillón J

Revista espanola de enfermedades digestivas 2017; (109(6)):480-481 doi:10.17235/reed.2017.4725/2016.

Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group.

Nell S, Verkooijen HM, Pieterman CRC, et al.

Annals of surgery 2018; (267(6)):1155-1160 doi:10.1097/SLA.0000000000002183.

Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.

Jun E, Kim SC, Song KB, et al.

Surgery 2017; (162(1)):120-130 doi:10.1016/j.surg.2017.01.019.

Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Miki M, Ito T, Hijioka M, et al.

Japanese journal of clinical oncology 2017; (47(6)):520-528 doi:10.1093/jjco/hyx032.

Pancreatic neuroendocrine tumors.

Sun J

Intractable & rare diseases research 2017; (6(1)):21-28 doi:10.5582/irdr.2017.01007.

Image Findings of a Rare Case of Neuroendocrine Tumor Metastatic to Orbital Extraocular Muscle in Gallium-68 DOTANOC Positron Emission Tomography/Computed Tomography and Therapy with Lutetium-177 DOTATATE.

Kamaleshwaran KK, Joseph J, Upadhya I, Shinto AS

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2017; (32(2)):125-127 doi:10.4103/0972-3919.202236.

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Bozkurt MF, Virgolini I, Balogova S, et al.

European journal of nuclear medicine and molecular imaging 2017; (44(9)):1588-1601 doi:10.1007/s00259-017-3728-y.

Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.

Singh S, Sivajohanathan D, Asmis T, et al.

Current oncology (Toronto, Ont.) 2017; (24(4)):249-255 doi:10.3747/co.24.3634.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Oronsky B, Ma PC, Morgensztern D, Carter CA

Neoplasia (New York, N.Y.) 2017; (19(12)):991-1002 doi:10.1016/j.neo.2017.09.002.

Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?

Gorelik M, Ahmad M, Grossman D, et al.

The Surgical clinics of North America 2018; (98(1)):157-167 doi:10.1016/j.suc.2017.09.014.

Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs.

Lv Y, Han X, Zhang C, et al.

Endocrine connections 2018; (7(1)):169-178 doi:10.1530/EC-17-0276.

Significance of splenic uptake on somatostatin receptor imaging studies.

Sarikaya I, Sarikaya A, Alnafisi N, Alenezi S

Nuclear medicine review. Central & Eastern Europe 2018; (21(1)):66-70 doi:10.5603/NMR.a2018.0012.

An observational analysis of insulinoma from a single institution.

Shao S, Zeng Z, Hu S

QJM : monthly journal of the Association of Physicians 2018; (111(4)):237-241 doi:10.1093/qjmed/hcy006.

Glucagonoma and the glucagonoma syndrome.

Song X, Zheng S, Yang G, et al.

Oncology letters 2018; (15(3)):2749-2755 doi:10.3892/ol.2017.7703.

The prognostic impact of primary tumor resection in pancreatic neuroendocrine tumors with synchronous multifocal liver metastases.

Lin C, Dai H, Hong X, et al.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018; (18(5)):608-614 doi:10.1016/j.pan.2018.04.014.

177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.

Demirci E, Kabasakal L, Toklu T, et al.

Nuclear medicine communications 2018; (39(8)):789-796 doi:10.1097/MNM.0000000000000874.

The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.

Inzani F, Petrone G, Rindi G

Endocrinology and metabolism clinics of North America 2018; (47(3)):463-470 doi:10.1016/j.ecl.2018.04.008.

Novel Functional Imaging of Neuroendocrine Tumors.

Sundin A

Endocrinology and metabolism clinics of North America 2018; (47(3)):505-523 doi:10.1016/j.ecl.2018.04.003.

Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1.

Albers MB, Manoharan J, Bollmann C, et al.

World journal of surgery 2019; (43(2)):552-558 doi:10.1007/s00268-018-4809-1.

Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).

Scott AT, Breheny PJ, Keck KJ, et al.

Surgery 2019; (165(1)):166-175 doi:10.1016/j.surg.2018.04.070.

The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8-institution study from the US Neuroendocrine Tumor Study Group.

Zaidi MY, Lopez-Aguiar AG, Poultsides GA, et al.

Journal of surgical oncology 2019; (119(1)):5-11 doi:10.1002/jso.25306.

The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.

Batukbhai BDO, De Jesus-Acosta A

Pancreas 2019; (48(1)):9-21 doi:10.1097/MPA.0000000000001189.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).

González-Flores E, Serrano R, Sevilla I, et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019; (21(1)):55-63 doi:10.1007/s12094-018-1980-7.

What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?

Choe J, Kim KW, Kim HJ, et al.

Korean journal of radiology 2019; (20(1)):5-17 doi:10.3348/kjr.2018.0040.

Pancreatic islet cell tumors in adolescents and young adults.

Waters AM, Maizlin II, Russell RT, et al.

Journal of pediatric surgery 2019; (54(10)):2103-2106 doi:10.1016/j.jpedsurg.2019.01.060.

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.

Stueven AK, Kayser A, Wetz C, et al.

International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20123049.

Evaluation and Management of Neuroendocrine Tumors of the Pancreas.

Scott AT, Howe JR

The Surgical clinics of North America 2019; (99(4)):793-814 doi:10.1016/j.suc.2019.04.014.

Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.

Kamilaris CDC, Stratakis CA

Frontiers in endocrinology 2019; (10()):339 doi:10.3389/fendo.2019.00339.

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

Hennrich U, Kopka K

Pharmaceuticals (Basel, Switzerland) 2019; (12(3)) doi:10.3390/ph12030114.

Laparoscopic spleen-preserving pancreatic resection for intrapancreatic accessory spleen: Case report.

Li L, Liu X, Chen J, et al.

Medicine 2019; (98(31)):e16488 doi:10.1097/MD.0000000000016488.

The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.

Nuñez JE, Donadio M, Filho DR, et al.

Journal of gastrointestinal oncology 2019; (10(4)):645-651 doi:10.21037/jgo.2019.01.33.

A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.

Fang JM, Shi J

Archives of pathology & laboratory medicine 2019; (143(11)):1317-1326 doi:10.5858/arpa.2019-0338-RA.

Overview of Genetically Determined Diseases/Multiple Endocrine Neoplasia Syndromes Predisposing to Endocrine Tumors.

Decmann A, Patócs A, Igaz P

Experientia supplementum (2012) 2019; (111()):105-127 doi:10.1007/978-3-030-25905-1_7.

177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Satapathy S, Mittal BR

Nuclear medicine communications 2019; (40(12)):1195-1203 doi:10.1097/MNM.0000000000001103.

Chromogranin A pathway: from pathogenic molecule to renal disease.

Mir SA, Biswas N, Cheung W, et al.

Journal of hypertension 2020; (38(3)):456-466 doi:10.1097/HJH.0000000000002295.

Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy.

O'Neill E, Kersemans V, Allen PD, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020; (61(5)):743-750 doi:10.2967/jnumed.119.232934.

Surgical management of pancreatic neuroendocrine tumors: an introduction.

Hain E, Sindayigaya R, Fawaz J, et al.

Expert review of anticancer therapy 2019; (19(12)):1089-1100 doi:10.1080/14737140.2019.1703677.

Ectopic insulinoma: case report.

Sun M, Luo Y, You Y, et al.

BMC surgery 2019; (19(1)):197 doi:10.1186/s12893-019-0661-y.

Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.

Crown A, Rocha FG, Raghu P, et al.

Journal of surgical oncology 2020; (121(3)):480-485 doi:10.1002/jso.25812.

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Howe JR, Merchant NB, Conrad C, et al.

Pancreas 2020; (49(1)):1-33 doi:10.1097/MPA.0000000000001454.

The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas.

Skoura E, Priftakis D, Novruzov F, et al.

Nuclear medicine communications 2020; (41(2)):169-174 doi:10.1097/MNM.0000000000001130.

Remember the Pitfall: Intrapancreatic Accessory Spleen Mimicking Neuroendocrine Neoplasm.

Rosar F, Ries M, Khreish F, Ezziddin S

Clinical nuclear medicine 2020; (45(3)):250-251 doi:10.1097/RLU.0000000000002945.

Overview and Current Status of Peptide Receptor Radionuclide Therapy.

Bushnell DL, Bodeker KL

Surgical oncology clinics of North America 2020; (29(2)):317-326 doi:10.1016/j.soc.2019.11.005.

Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.

Marques B, Monteiro AR, Martins RG, et al.

Pancreas 2020; (49(3)):e19-e20 doi:10.1097/MPA.0000000000001514.

Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.

Taskin OC, Clarke CN, Erkan M, et al.

Journal of gastrointestinal oncology 2020; (11(3)):548-558 doi:10.21037/jgo.2020.03.07.

Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Tanaka M, Heckler M, Mihaljevic AL, et al.

Annals of surgical oncology 2021; (28(3)):1614-1624 doi:10.1245/s10434-020-08850-7.

mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).

Zanini S, Renzi S, Giovinazzo F, Bermano G

Frontiers in endocrinology 2020; (11()):562505 doi:10.3389/fendo.2020.562505.

Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.

Lam AK, Ishida H

Histology and histopathology 2021; (36(4)):367-382 doi:10.14670/HH-18-288.

Comparison between EUS-guided fine-needle aspiration cytology and EUS-guided fine-needle biopsy histology for the evaluation of pancreatic neuroendocrine tumors.

Crinò SF, Ammendola S, Meneghetti A, et al.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(2)):443-450 doi:10.1016/j.pan.2020.12.015.

Comparison of clinical outcomes between enucleation and regular pancreatectomy in patients with non-functional pancreatic neuroendocrine tumors: a retrospective multicenter and propensity score-matched study.

Yang Z, Gao H, Lu J, et al.

Japanese journal of clinical oncology 2021; (51(4)):595-603 doi:10.1093/jjco/hyaa246.

Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort.

van Beek DJ, Nell S, Vorselaars WMCM, et al.

Annals of surgical oncology 2021; (28(8)):4387-4399 doi:10.1245/s10434-020-09496-1.

The evolving role of EUS-guided tissue acquisition.

Ang TL, Wang LM

Journal of digestive diseases 2021; (22(4)):204-213 doi:10.1111/1751-2980.12976.

Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA).

Heidsma CM, Engelsman AF, van Dieren S, et al.

The British journal of surgery 2021; (108(8)):888-891 doi:10.1093/bjs/znab088.

Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports.

Mowrey K, Northrup H, Rougeau P, et al.

Frontiers in neurology 2021; (12()):627672 doi:10.3389/fneur.2021.627672.

The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours.

Cuthbertson DJ, Barriuso J, Lamarca A, et al.

Frontiers in endocrinology 2021; (12()):654975 doi:10.3389/fendo.2021.654975.

Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.

Modlin IM, Kidd M, Frilling A, et al.

Annals of surgery 2021; (274(3)):481-490 doi:10.1097/SLA.0000000000005026.

Technical aspects of paediatric robotic pancreatic enucleation based on a case of an insulinoma.

Schulte Am Esch J, Krüger M, Barthlen W, et al.

The international journal of medical robotics + computer assisted surgery : MRCAS 2021; (17(6)):e2317 doi:10.1002/rcs.2317.

Solid pseudopapillary neoplasm of the pancreas.

Omiyale AO

World journal of hepatology 2021; (13(8)):896-903 doi:10.4254/wjh.v13.i8.896.

Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls.

Konukiewitz B, Jesinghaus M, Kasajima A, Klöppel G

Virchows Archiv : an international journal of pathology 2022; (480(2)):247-257 doi:10.1007/s00428-021-03211-5.

Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.

Mennetrey C, Le Bras M, Bando-Delaunay A, et al.

The Journal of clinical endocrinology and metabolism 2022; (107(5)):e2056-e2064 doi:10.1210/clinem/dgab891.

DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.

Simon T, Riemer P, Jarosch A, et al.

Genome medicine 2022; (14(1)):24 doi:10.1186/s13073-022-01018-w.

Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.

Ishida H, Lam AK

Critical reviews in oncology/hematology 2022; (172()):103648 doi:10.1016/j.critrevonc.2022.103648.

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

Love C, Desai NB, Abraham T, et al.

American journal of clinical oncology 2022; (45(6)):233-242 doi:10.1097/COC.0000000000000903.

Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Hope TA, Pavel M, Bergsland EK

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(24)):2818-2829 doi:10.1200/JCO.22.00176.

Surgery or active surveillance for pNETs < 2 cm: Preliminary results from a single center Brazilian cohort.

Arra DASM, Ribeiro HSC, Henklain G, et al.

Journal of surgical oncology 2022; (126(1)):168-174 doi:10.1002/jso.26931.

The management of small nonfunctional pancreatic neuroendocrine tumors: It's time to define the high-risk features.

Tan Q, Chengzhi X, Chen Y

Journal of surgical oncology 2022; (126(6)):1135-1136 doi:10.1002/jso.27025.

Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.

Yumoto S, Nakagawa S, Hayashi H, et al.

Clinical journal of gastroenterology 2022; (15(6)):1136-1144 doi:10.1007/s12328-022-01689-3.

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report.

Kumar A, Tanwar S, Gupta S, et al.

Exploration of targeted anti-tumor therapy 2022; (3(3)):392-397 doi:10.37349/etat.2022.00089.

Genetics of Pancreatic Neuroendocrine Tumors.

Mohindroo C, McAllister F, De Jesus-Acosta A

Hematology/oncology clinics of North America 2022; (36(5)):1033-1051 doi:10.1016/j.hoc.2022.07.005.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

Kunz PL, Graham NT, Catalano PJ, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(7)):1359-1369 doi:10.1200/JCO.22.01013.

Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.

Greenberg J, Limberg J, Verma A, et al.

JCI insight 2022; (7(23)).

Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management.

Ramesh A, Chatterjee A, Subramaniam RM

PET clinics 2023; (18(2)):161-168 doi:10.1016/j.cpet.2022.10.002.

[Enucleation of pancreatic tumors: a multiple-center study].

Solodkiy VA, Kriger AG, Akhaladze GG, et al.

Khirurgiia 2023; 13-20 doi:10.17116/hirurgia202302113.

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.

di Santo G, Santo G, Sviridenko A, Virgolini I

Theranostics 2024; (14(3)):940-953 doi:10.7150/thno.91268.

Head-to-head: Should Ki67 proliferation index be included in the formal classification of pulmonary neuroendocrine neoplasms?

Pelosi G, Travis WD

Histopathology 2024; (85(4)):535-548 doi:10.1111/his.15206.

Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms.

Albers MB, Sevcik M, Wiese D, et al.

Scientific reports 2024; (14(1)):18507 doi:10.1038/s41598-024-68290-1.

Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.

De Jesus-Acosta A, Mohindroo C

JCO precision oncology 2024; (8()):e2400221 doi:10.1200/PO.24.00221.

Can CT Image Reconstruction Parameters Impact the Predictive Value of Radiomics Features in Grading Pancreatic Neuroendocrine Neoplasms?

Tixier F, Lopez-Ramirez F, Blanco A, et al.

Bioengineering (Basel, Switzerland) 2025; (12(1)) doi:10.3390/bioengineering12010080.

[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors.

Kim SJ, Cha J, Lee HS, et al.

Cancers 2025; (17(9)) doi:10.3390/cancers17091487.

Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Khajeh E, Shahrbaf M, Apostolidis L, et al.

Annals of surgical oncology 2025; (32(10)):7532-7549 doi:10.1245/s10434-025-17819-3.

Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.

Keretić D, Bašković M

Diagnostics (Basel, Switzerland) 2025; (15(17)) doi:10.3390/diagnostics15172176.

Interpretable deep learning model and nomogram for predicting pathological grading of PNETs based on endoscopic ultrasound.

Mo S, Zhang Y, Liu N, et al.

BMC medical informatics and decision making 2025; (25(1)):360 doi:10.1186/s12911-025-03193-3.

Key Biomarker Correlations in Cutaneous Melanoma: Implications for Diagnostic, Prognostic, and Therapeutic Strategies-A Retrospective Single-Centered Study.

Costache M, Gheorghişan-Gălățeanu AA, Derewicz D, et al.

Medicina (Kaunas, Lithuania) 2025; (61(10)) doi:10.3390/medicina61101733.

Current Medical Controversies in Zollinger-Ellison Syndrome.

Jensen RT, Ramos-Alvarez I, Norton JA

Biomedicines 2025; (13(12)) doi:10.3390/biomedicines13123051.